CA3179937A1 - Phthalocyanine dye compounds, conjugates and methods of use thereof - Google Patents

Phthalocyanine dye compounds, conjugates and methods of use thereof

Info

Publication number
CA3179937A1
CA3179937A1 CA3179937A CA3179937A CA3179937A1 CA 3179937 A1 CA3179937 A1 CA 3179937A1 CA 3179937 A CA3179937 A CA 3179937A CA 3179937 A CA3179937 A CA 3179937A CA 3179937 A1 CA3179937 A1 CA 3179937A1
Authority
CA
Canada
Prior art keywords
optionally substituted
independently
tautomer
stereoisomer
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3179937A
Other languages
English (en)
French (fr)
Inventor
Juan Betancort
Lew MAKINGS
Torsten Wiemann
Robert J. Hoey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rakuten Medical Inc
Original Assignee
Rakuten Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rakuten Medical Inc filed Critical Rakuten Medical Inc
Publication of CA3179937A1 publication Critical patent/CA3179937A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B47/00—Porphines; Azaporphines
    • C09B47/04—Phthalocyanines abbreviation: Pc
    • C09B47/30—Metal-free phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0036—Porphyrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B47/00—Porphines; Azaporphines
    • C09B47/04—Phthalocyanines abbreviation: Pc
    • C09B47/08—Preparation from other phthalocyanine compounds, e.g. cobaltphthalocyanineamine complex
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B47/00—Porphines; Azaporphines
    • C09B47/04—Phthalocyanines abbreviation: Pc
    • C09B47/32—Cationic phthalocyanine dyes
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B69/00—Dyes not provided for by a single group of this subclass
    • C09B69/008—Dyes containing a substituent, which contains a silicium atom
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E10/00—Energy generation through renewable energy sources
    • Y02E10/50—Photovoltaic [PV] energy
    • Y02E10/542—Dye sensitized solar cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Radiation-Therapy Devices (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cosmetics (AREA)
  • Detergent Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CA3179937A 2020-04-10 2021-04-09 Phthalocyanine dye compounds, conjugates and methods of use thereof Pending CA3179937A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063008476P 2020-04-10 2020-04-10
US202063008502P 2020-04-10 2020-04-10
US63/008,476 2020-04-10
US63/008,502 2020-04-10
PCT/US2021/026705 WO2021207691A1 (en) 2020-04-10 2021-04-09 Phthalocyanine dye compounds, conjugates and methods of use thereof

Publications (1)

Publication Number Publication Date
CA3179937A1 true CA3179937A1 (en) 2021-10-14

Family

ID=78022788

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3179937A Pending CA3179937A1 (en) 2020-04-10 2021-04-09 Phthalocyanine dye compounds, conjugates and methods of use thereof

Country Status (10)

Country Link
US (2) US11466158B2 (https=)
EP (1) EP4132583A4 (https=)
JP (3) JP7125828B2 (https=)
KR (1) KR20230009890A (https=)
CN (1) CN115942958A (https=)
AU (1) AU2021251873A1 (https=)
BR (1) BR112022020521A2 (https=)
CA (1) CA3179937A1 (https=)
MX (1) MX2022012721A (https=)
WO (1) WO2021207691A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7760124B2 (ja) * 2020-02-05 2025-10-27 国立大学法人 東京大学 フタロシアニン染料と抗体又はペプチドとのコンジュゲート
WO2021207691A1 (en) 2020-04-10 2021-10-14 Rakuten Medical, Inc. Phthalocyanine dye compounds, conjugates and methods of use thereof
JP2024505556A (ja) 2021-02-02 2024-02-06 ラクテン・メディカル，インコーポレイテッド がん、腫瘍および腫瘍細胞の局所および全身処置のための方法
US12115223B2 (en) 2021-04-22 2024-10-15 The University Of Tokyo Conjugate of biotin-modified dimer and phthalocyanine dye
CN113943305B (zh) * 2021-11-15 2022-12-30 中国科学技术大学 酞菁荧光分子化合物、制备方法、酞菁荧光纳米材料
AU2023221861A1 (en) 2022-02-18 2024-09-05 Rakuten Medical, Inc. Anti-programmed death-ligand 1 (pd-l1) antibody molecules, encoding polynucleotides, and methods of use
EP4615863A1 (en) 2022-11-11 2025-09-17 Rakuten Medical, Inc. Engineered interleukin-15 polypeptides, complexes and uses thereof
EP4435060A1 (en) 2023-03-23 2024-09-25 Albert-Ludwigs-Universität Freiburg Silicon phthalocyanine and tribenzophthalocyanine dyes and their use in diagnosis and therapy
WO2025035196A1 (pt) * 2023-08-11 2025-02-20 Use Phitta Cream Ltda - Epp Creme hidratante com proteção antisséptica de ação prolongada para as mãos

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2082934C (en) * 1990-05-15 2003-08-05 Walter B. Dandliker Phthalocyanatopolyethylene glycol, and phthalocyanato saccharides as fluorescent digoxin reagents
US6060598A (en) * 1990-05-15 2000-05-09 Hyperion, Inc. Fluorescence immunoassays using fluorescent dyes free of aggregation and serum binding
ES2163393T3 (es) 1990-05-15 2002-02-01 Hyperion Inc Porfirina fluorescente y ftalocianina fluorescente - derivados de polietilenglicol, poliol y sacaridos como sondas fluorescentes.
US5484778C1 (en) * 1990-07-17 2001-05-08 Univ Cleveland Hospitals Phthalocynine photosensitizers for photodynamic therapy and methods for their use
US5763602A (en) * 1996-10-01 1998-06-09 Li; Ying-Syi Methods of syntheses of phthalocyanine compounds
US7005518B2 (en) * 2002-10-25 2006-02-28 Li-Cor, Inc. Phthalocyanine dyes
CN1315850C (zh) 2004-06-11 2007-05-16 福州大学 轴向取代酞菁配合物、它的制备及其在光动力治疗中的应用
CN103539799B (zh) 2013-08-29 2016-01-06 中国医学科学院生物医学工程研究所 一种水溶性氨基多羧酸修饰酞菁化合物的制备方法和用途
EP3046583B1 (en) 2013-09-18 2019-02-13 Aura Biosciences, Inc. Virus-like particle conjugates for treatment of tumors
ES2889904T3 (es) 2015-08-18 2022-01-14 Rakuten Medical Inc Conjugados de colorante de ftalocianina y su almacenamiento
US11154620B2 (en) 2015-08-18 2021-10-26 Rakuten Medical, Inc. Compositions, combinations and related methods for photoimmunotherapy
CA3026651A1 (en) 2016-06-09 2017-12-14 Blinkbio, Inc. Silanol based therapeutic payloads
CA3070469C (en) 2016-10-25 2022-06-21 Rakuten Medical, Inc. Light diffusing devices for use in photoimmunotherapy
US10416366B2 (en) 2016-10-25 2019-09-17 Rakuten Medical, Inc. Light diffusing devices for use in photoimmunotherapy
JP2020508323A (ja) * 2017-02-23 2020-03-19 ラクテン メディカル インコーポレイテッド 光免疫療法のための治療用組成物および関連する方法
US11879014B2 (en) 2017-03-17 2024-01-23 Tusk Therapeutics Ltd. Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
EP3649153B8 (en) 2017-07-06 2025-07-16 Tusk Therapeutics Ltd Fc optimised anti-cd25 antibodies for tumor specific cell depletion
JP2020017910A (ja) 2018-07-27 2020-01-30 ソニーセミコンダクタソリューションズ株式会社 ストリーキング補正回路、撮像装置、及び、電子機器
JP7625188B2 (ja) * 2019-09-30 2025-02-03 国立大学法人 東京大学 ビオチン改変二量体とフタロシアニン染料とのコンジュゲート
JP7760124B2 (ja) 2020-02-05 2025-10-27 国立大学法人 東京大学 フタロシアニン染料と抗体又はペプチドとのコンジュゲート
WO2021207691A1 (en) * 2020-04-10 2021-10-14 Rakuten Medical, Inc. Phthalocyanine dye compounds, conjugates and methods of use thereof
WO2022216978A1 (en) 2021-04-09 2022-10-13 Rakuten Medical, Inc. Phthalocyanine dye compounds, conjugates and methods of use thereof

Also Published As

Publication number Publication date
JP2022527672A (ja) 2022-06-02
MX2022012721A (es) 2023-01-16
US12448518B2 (en) 2025-10-21
EP4132583A1 (en) 2023-02-15
JP2022191210A (ja) 2022-12-27
JP7125828B2 (ja) 2022-08-25
US20230399515A1 (en) 2023-12-14
EP4132583A4 (en) 2024-11-13
CN115942958A (zh) 2023-04-07
US11466158B2 (en) 2022-10-11
JP2022191209A (ja) 2022-12-27
WO2021207691A1 (en) 2021-10-14
US20220010140A1 (en) 2022-01-13
KR20230009890A (ko) 2023-01-17
AU2021251873A1 (en) 2022-11-10
BR112022020521A2 (pt) 2023-03-07

Similar Documents

Publication Publication Date Title
US12448518B2 (en) Phthalocyanine dye compounds, conjugates and methods of use thereof
TW202330037A (zh) 用於抗體藥物綴合物之連接子
US20190365897A1 (en) Therapeutic compositions and related methods for photoimmunotherapy
KR20250080893A (ko) 효소 절단 링커 및 이를 포함하는 리간드-에리불린 접합체
EP3762037B1 (en) Releasable antibody conjugates
US20240285765A1 (en) Phthalocyanine dye compounds, conjugates and methods of use thereof
CA3210086A1 (en) Near infrared photoimmunotherapy (nir-pit) combination therapy to treat cancer
JP2025525451A (ja) Ｃｄ２５特異的抗体およびその使用
JP2025533191A (ja) 化合物、組成物および方法
WO2023172951A1 (en) Methods of treating solid tumors with anti-tissue factor antibody-drug conjugates
CA3195303A1 (en) Glycoconjugates
HK40091368A (zh) 酞菁染料化合物、缀合物及其使用方法
CN119947761B (zh) 抗b7h3和pd-l1的双特异性抗体药物偶联物及其制备方法和用途
TWI913660B (zh) 酶裂解連接子及包含其的配體-艾瑞布林偶聯物
WO2026037321A1 (en) Compounds, compositions and methods
CN121991160A (zh) 一种靶向蛋白降解剂及其药物组合物和应用
TW202546007A (zh) 抗體藥物結合物
KR20260040624A (ko) c-Met를 표적으로 하는 항체-약물 접합체 및 이의 의학적 용도
HU231675B1 (hu) Heterociklusos aromás rekonjugáló ágensek antitestek vagy antitest származékok rekonjugációjához
CA3238784A1 (en) Stapled peptide-antibody conjugates (spacs) and uses thereof
WO2025130990A1 (zh) 肿瘤微环境激活的药物偶联物及抗体药物偶联物
TW202517255A (zh) 化合物、組合物及方法
EP4543893A1 (en) N-substituted indole derivatives and conjugates for the treatment of cancer

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250404

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250404

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260203